High glucose reduces hepatic glycogenesis by suppression of microRNA152

Xiaoyun Zhao1, Yonggang Lu1, Fenghong Wang1

  • 1Clinical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei 050057, P.R. China.

Insights

High glucose levels reduce miR-152 expression, impairing AKT/GSK pathway activation and glycogen synthesis in mouse hepatocytes. This study reveals miR-152

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are endogenous RNA molecules regulating gene expression post-transcriptionally.
  • miR-152 is known to affect oncogenes and tumor suppressors in cancer.
  • The role of miR-152 in hepatic insulin resistance and glucose metabolism is largely unknown.

Purpose of the Study:

  • To investigate the role of miR-152 in regulating glucose metabolism and insulin signaling in mouse hepatocytes.
  • To determine the effect of high glucose on miR-152 expression and its downstream targets.

Main Methods:

  • Primary mouse hepatocytes and NCTC 1469 cells were exposed to high glucose (25 mM for 48 h).
  • miR-152 mimic and inhibitor transfections were performed to modulate miR-152 levels.
  • Western blotting and glycogen assays were used to assess protein phosphorylation and glycogen synthesis.

Main Results:

  • High glucose reduced AKT and GSK-3 activation and glycogen synthesis in hepatocytes.
  • High glucose suppressed miR-152 expression in hepatocytes.
  • Inhibition of miR-152 impaired glycogen synthesis and AKT/GSK phosphorylation, while miR-152 upregulation reversed these effects.

Conclusions:

  • High glucose impairs the AKT/GSK pathway and hepatic glycogen synthesis.
  • miR-152 downregulation contributes to high glucose-induced metabolic dysfunction in hepatocytes.
  • miR-152 plays a crucial role in modulating hepatic glucose metabolism via the AKT/GSK pathway.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
949
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.4K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K